BofA lowered the firm’s price target on 4D Molecular (FDMT) to $42 from $46 on Friday and kept a Buy rating on the shares. The firm notes 4D ...

Research led by Brock University has found a possible cure for lung diseases typically found in older adults, such as pulmonary fibrosis. The findings are published in the journal Aging Cell.

D Molecular Therapeutics reaches agreement with FDA for phase 3 trial design of DME candidate 4D-150, showing promising ...

Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose ...

Therapeutics announced topline interim data from Part 1 of the SPECTRA clinical trial evaluating 4D-150 in diabetic macular ...

The following is a summary of “Microcystoid macular edema in epiretinal membrane: not a retrograde maculopathy,” published in ...

Drug-induced lung disease cases in France mostly involved ILD, pulmonary edema, and pulmonary fibrosis, largely linked to cancer and CV drugs.

The phase 3 trial showed biosimilar CT-P42 (Celltrion) is therapeutically equivalent to reference aflibercept in improving ...

Dogs can develop edema around the body. The condition can range from mild to severe and even life-threatening, depending on ...

Investigators conducted a meta-analysis of randomized controlled trials to assess the efficacy and safety of brolucizumab ...

A recent study that compared 2 anti-vascular endothelial growth factor drugs for treating diabetic macular edema (DME) found that brolucizumab (Beovu, Novartis) was non-inferior in functional outcomes ...

Curacle presented the results of its phase 2a clinical trial of CU06 for diabetic macular edema (DME) at the 4th Asia Retina Congress. This meeting is being held alongside the 2024 Annual Meeting of ...